Combination immunotherapy reverses resistance to PD-1 inhibitors in patients with advanced melanoma

By | April 9, 2022
Patients with advanced melanoma whose cancer does not respond to treatment with widely used immunotherapy drugs known as PD-1 inhibitors are often switched to treatment with a second type of immunotherapy drug – a CTLA-4 inhibitor such as the drug ipilimumab.